Journal of Cancer Immunology

Review Article Open Access

Higher Frequency and Poor Prognosis with COVID-19 Associated Cytokine Storm among Cancer Patients: Between Two Fires

Murat Bektaş , Nevzat Koca , Burak İnce

At the end of 2019, the world faced a new disease, COVID-19 caused by SARS-Cov-2 and became a pandemic within few weeks. The fact that COVID-19 spreads very quickly and has
significant morbidity and mortality had devastating effects all over the world.

Commentary Open Access

Can Butein be a Future Candidate for the Treatment of Advance Metastatic Thyroid Cancer?

Devavrat Tripathi , Savita Kulkarni

The incidence and prevalence of papillary thyroid cancer (PTC) are increasing worldwide and it is the 5th most common endocrine cancer in females.

Review Article Open Access

Performance of the Tyrer-Cuzick 8 Breast Cancer Risk Model Across Races: A Review

Melissa D Porterhouse , Rosalinda Alvarado

The Tyrer-Cuzick (TC) model is a breast cancer risk assessment tool that provides women with their risk of developing breast cancer based on genetic and personal factors. The most recent version of the TC model, TC8, is the first version to include breast density as a risk factor for breast cancer.

Commentary Open Access

Clutch Control: Changing the Speed and Direction of CAR-T Cell Therapy

Alberto Nobili , Aya Kobayashi , Patrick C. Gedeon , Carl D. Novina

The adoptive transfer of T cells expressing chimeric antigen receptors (CAR-T cells) has revolutionized the treatment of hematological malignancies, providing unmatched clinical responses in adults and children with relapsed or refractory B cell malignancies.

Perspective Open Access

Molecular Iodine Misconceptions: A Novel Formulation Approach to Topical Iodine

Jack Kessler

My team of chemists have formulated molecular iodine (I2) so it can be studied independent of other iodine species.The initial impetus for this effort was to allow for a higher concentration of biocidal I2 that would not evaporate into the atmosphere when applied to skin.

Commentary Open Access

A Surprising Benefit of Cysteine Capping for Antibody Drug Conjugates

Aaron M. D’Antona , Kaushik Dutta , Xiaotian Zhong

Antibody-drug conjugates (ADCs), combining the best features of monoclonal antibodies and small molecule drugs, are considered the “guided missiles” for cancer therapy, with eleven FDA-approved products. Yet the ADC modality still presents a huge challenge to drug developers, especially for targeting tumors with low abundance and/or heterogeneity of tumor-associated antigens.